{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T15:57:52Z","timestamp":1791734272109,"version":"4.3.4"},"reference-count":153,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T00:00:00Z","timestamp":1759363200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.mdpi.com"],"crossmark-restriction":true},"short-container-title":["Cancers"],"abstract":"<jats:p>Peritoneal carcinomatosis (PC) and malignant pleural effusions (MPE) are two common complications of cancers metastatic to the respective body cavities. A PC diagnosis indicates metastasis to the tissue lining the abdominal cavity and is most common in patients with gastrointestinal and gynecological cancers. It is often accompanied by ascites, an accumulation of serous fluid in the abdomen. MPE presents as the accumulation of fluid in the space between the lungs and chest wall. It is a common terminal event in patients diagnosed with breast cancer, lung cancer, lymphoma, and mesothelial cancers, and less commonly, in a wide variety of other epithelial cancers. Due to the aggressive nature of cavitary tumors, the outcome of current treatments for both PC and MPE remains bleak. Although PC and MPE are characteristically affected by different sets of primary tumors (lung\/breast\/mesothelioma for MPE and gynecologic\/gastrointestinal for PC), their environments share common cytokines and cellular components. Owing to the unique cytokine and chemokine content, this environment promotes aggressive tumor behavior and paradoxically both recruits and suppresses central memory and effector memory T cells. The cellular and secretomic complexity of the cavitary tumor environment renders most currently available therapeutics ineffective but also invites approaches that leverage the robust T-cell infiltrate while addressing the causes of local suppression of anti-tumor immunity. Interactions between the heterogeneous components of the tumor environment are an area of active research. We highlight the roles of the immune cell infiltrate, stromal cells, and tumor cells, and the soluble products that they secrete into their environment. A more comprehensive understanding of the cavitary tumor environment can be expected to lead to better immunotherapeutic approaches to these devastating conditions.<\/jats:p>","DOI":"10.3390\/cancers17193217","type":"journal-article","created":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T15:07:48Z","timestamp":1759417668000},"page":"3217","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The Tumor Environment in Peritoneal Carcinomatosis and Malignant Pleural Effusions: Implications for Therapy"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0473-4824","authenticated-orcid":false,"given":"Paige O.","family":"Mirsky","sequence":"first","affiliation":[{"name":"Allegheny Health Network Research Institute, West Penn Hospital, 4800 Friendship Avenue, 2102 West Tower, Pittsburgh, PA 15224, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-3935-5316","authenticated-orcid":false,"given":"Patrick L.","family":"Wagner","sequence":"additional","affiliation":[{"name":"Allegheny Health Network Research Institute, West Penn Hospital, 4800 Friendship Avenue, 2102 West Tower, Pittsburgh, PA 15224, USA"},{"name":"Department of Surgery, Drexel University College of Medicine, 2900 W Queen Ln, Philadelphia, PA 19129, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maja","family":"Mandic-Popov","sequence":"additional","affiliation":[{"name":"Allegheny Health Network Research Institute, West Penn Hospital, 4800 Friendship Avenue, 2102 West Tower, Pittsburgh, PA 15224, USA"},{"name":"Department of Medicine, Drexel University College of Medicine, 2900 W Queen Ln, Philadelphia, PA 19129, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera S.","family":"Donnenberg","sequence":"additional","affiliation":[{"name":"Department of Cardiothoracic Surgery, Hillman Cancer Center, University of Pittsburgh School of Medicine, 5117 Centre Avenue, Pittsburgh, PA 15213, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6723-3330","authenticated-orcid":false,"given":"Albert D.","family":"Donnenberg","sequence":"additional","affiliation":[{"name":"Allegheny Health Network Research Institute, West Penn Hospital, 4800 Friendship Avenue, 2102 West Tower, Pittsburgh, PA 15224, USA"},{"name":"Department of Medicine, Drexel University College of Medicine, 2900 W Queen Ln, Philadelphia, PA 19129, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,10,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.apsb.2015.07.005","article-title":"Cancer metastases: Challenges and opportunities","volume":"5","author":"Guan","year":"2015","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1002\/1097-0142(19890115)63:2<364::AID-CNCR2820630228>3.0.CO;2-V","article-title":"Peritoneal carcinomatosis in nongynecologic malignancy. A prospective study of prognostic factors","volume":"63","author":"Chu","year":"1989","journal-title":"Cancer"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1038\/bjc.2013.82","article-title":"Impact of peritoneal carcinomatosis in the disease history of colorectal cancer management: A longitudinal experience of 2406 patients over two decades","volume":"108","author":"Kerscher","year":"2013","journal-title":"Br. J. Cancer"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"106802","DOI":"10.1016\/j.rmed.2022.106802","article-title":"Update on the diagnosis and management of malignant pleural effusions","volume":"196","author":"Bashour","year":"2022","journal-title":"Respir. Med."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Donnenberg, V.S., Luketich, J.D., Sultan, I., Lister, J., Bartlett, D.L., Ghosh, S., and Donnenberg, A.D. (2023). A maladaptive pleural environment suppresses preexisting anti-tumor activity of pleural infiltrating T cells. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1157697"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Lewis, C.R., Dadgar, N., Yellin, S.A., Donnenberg, V.S., Donnenberg, A.D., Bartlett, D.L., Allen, C.J., and Wagner, P.L. (2023). Regional Immunotherapy for Peritoneal Carcinomatosis in Gastroesophageal Cancer: Emerging Strategies to Re-Condition a Maladaptive Tumor Environment. Cancers, 15.","DOI":"10.3390\/cancers15205107"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Ornella, M.S.C., Badrinath, N., Kim, K.-A., Kim, J.H., Cho, E., Hwang, T.-H., and Kim, J.-J. (2023). Immunotherapy for Peritoneal Carcinomatosis: Challenges and Prospective Outcomes. Cancers, 15.","DOI":"10.3390\/cancers15082383"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Terri, M., Trionfetti, F., Montaldo, C., Cordani, M., Tripodi, M., Lopez-Cabrera, M., and Strippoli, R. (2021). Mechanisms of Peritoneal Fibrosis: Focus on Immune Cells\u2013Peritoneal Stroma Interactions. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.607204"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1177\/1742271X16680653","article-title":"Ascites matters","volume":"25","author":"Rudralingam","year":"2017","journal-title":"Ultrasound"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"89","DOI":"10.5114\/pjr.2023.125027","article-title":"Diagnosis and treatment of peritoneal carcinomatosis\u2014A comprehensive overview","volume":"88","author":"Szadkowska","year":"2023","journal-title":"Pol. J. Radiol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1186\/s12967-024-05205-8","article-title":"Targeting interleukin-6 as a treatment approach for peritoneal carcinomatosis","volume":"22","author":"Dadgar","year":"2024","journal-title":"J. Transl. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"87","DOI":"10.4240\/wjgs.v4.i4.87","article-title":"Malignant ascites: A review of prognostic factors, pathophysiology and therapeutic measures","volume":"4","author":"Sangisetty","year":"2012","journal-title":"World J. Gastrointest. Surg."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"102646","DOI":"10.1016\/j.ctrv.2023.102646","article-title":"Malignant ascites: Current therapy options and treatment prospects","volume":"121","author":"Berger","year":"2023","journal-title":"Cancer Treat. Rev."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"6456","DOI":"10.18632\/oncotarget.27290","article-title":"Secretome of pleural effusions associated with non-small cell lung cancer (NSCLC) and malignant mesothelioma: Therapeutic implications","volume":"10","author":"Donnenberg","year":"2019","journal-title":"Oncotarget"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/j.amjmed.2022.04.017","article-title":"Malignant Pleural Effusion: Presentation, Diagnosis, and Management","volume":"135","author":"Gayen","year":"2022","journal-title":"Am. J. Med."},{"key":"ref_16","first-page":"1211","article-title":"Diagnostic Approach to Pleural Effusion in Adults","volume":"73","author":"Porcel","year":"2006","journal-title":"Am. Fam. Physician"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Musso, V., Diotti, C., Palleschi, A., Tosi, D., Aiolfi, A., and Mendogni, P. (2021). Management of Pleural Effusion Secondary to Malignant Mesothelioma. J. Clin. Med., 10.","DOI":"10.3390\/jcm10184247"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s12931-024-02684-7","article-title":"Malignant pleural effusion: Current understanding and therapeutic approach","volume":"25","author":"Gonnelli","year":"2024","journal-title":"Respir. Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s41030-025-00300-7","article-title":"The Evolution of the Indwelling Pleural Catheter","volume":"11","author":"Baguneid","year":"2025","journal-title":"Pulm. Ther."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Zamboni, M.M., da Silva, C.T., Baretta, R., Cunha, E.T., and Cardoso, G.P. (2015). Important prognostic factors for survival in patients with malignant pleural effusion. BMC Pulm. Med., 15.","DOI":"10.1186\/s12890-015-0025-z"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/bs.ircmb.2022.04.013","article-title":"Chapter Two\u2014T cells in the peritoneum","volume":"Volume 371","author":"Aranda","year":"2022","journal-title":"International Review of Cell and Molecular Biology"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"9876014","DOI":"10.1155\/2018\/9876014","article-title":"Enhanced Suppressive Activity of Regulatory T Cells in the Microenvironment of Malignant Pleural Effusions","volume":"2018","author":"Budna","year":"2018","journal-title":"J. Immunol. Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1046\/j.1365-3083.1996.d01-297.x","article-title":"Normal human immune peritoneal cells: Subpopulations and functional characteristics","volume":"44","author":"Kubicka","year":"1996","journal-title":"Scand. J. Immunol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1164\/ajrccm.162.3.9910050","article-title":"Volume and cellular content of normal pleural fluid in humans examined by pleural lavage","volume":"162","author":"Noppen","year":"2000","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"817","DOI":"10.3727\/096504017X15130753659625","article-title":"The Peritoneal Macrophages in Inflammatory Diseases and Abdominal Cancers","volume":"26","author":"Liu","year":"2018","journal-title":"Oncol. Res."},{"key":"ref_26","first-page":"279","article-title":"Macrophages in malignant pleural effusions\u2014Alternatively activated tumor associated macrophages","volume":"16","author":"Kaczmarek","year":"2012","journal-title":"Contemp. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1007\/s10120-015-0579-8","article-title":"Tumor-associated macrophages of the M2 phenotype contribute to progression in gastric cancer with peritoneal dissemination","volume":"19","author":"Yamaguchi","year":"2016","journal-title":"Gastric Cancer"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Principe, N., Kidman, J., Lake, R.A., Lesterhuis, W.J., Nowak, A.K., McDonnell, A.M., and Chee, J. (2021). Malignant Pleural Effusions\u2014A Window Into Local Anti-Tumor T Cell Immunity?. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.672747"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1007\/s00262-015-1701-9","article-title":"CD163+CD14+ macrophages, a potential immune biomarker for malignant pleural effusion","volume":"64","author":"Wang","year":"2015","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1038\/labinvest.2013.69","article-title":"M2-polarized tumor-associated macrophages promoted epithelial\u2013mesenchymal transition in pancreatic cancer cells, partially through TLR4\/IL-10 signaling pathway","volume":"93","author":"Liu","year":"2013","journal-title":"Lab. Investig."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"81558","DOI":"10.18632\/oncotarget.18277","article-title":"Epithelial-to-mesenchymal transition, circulating tumor cells and cancer metastasis: Mechanisms and clinical applications","volume":"8","author":"Jie","year":"2017","journal-title":"Oncotarget"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"E82","DOI":"10.21037\/jtd.2019.06.11","article-title":"Epithelial-to-mesenchymal transition and drug resistance: Transitioning away from death","volume":"11","author":"Song","year":"2019","journal-title":"J. Thorac. Dis."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Szabo, P.M., Vajdi, A., Kumar, N., Tolstorukov, M.Y., Chen, B.J., Edwards, R., Ligon, K.L., Chasalow, S.D., Chow, K.-H., and Shetty, A. (2023). Cancer-associated fibroblasts are the main contributors to epithelial-to-mesenchymal signatures in the tumor microenvironment. Sci. Rep., 13.","DOI":"10.1038\/s41598-023-28480-9"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Mulet, M., Osuna-Gomez, R., Zamora, C., Porcel, J.M., Nieto, J.C., Perea, L., Pajares, V., Mu\u00f1oz-Fernandez, A.M., Calvo, N., and Sorolla, M.A. (2022). Influence of Malignant Pleural Fluid from Lung Adenocarcinoma Patients on Neutrophil Response. Cancers, 14.","DOI":"10.3390\/cancers14102529"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1158\/2326-6066.CIR-16-0297","article-title":"Myeloid-derived suppressor cells","volume":"5","author":"Gabrilovich","year":"2017","journal-title":"Cancer Immunol. Res."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Nair, R., Somasundaram, V., Kuriakose, A., Krishn, S.R., Raben, D., Salazar, R., and Nair, P. (2025). Deciphering T-cell exhaustion in the tumor microenvironment: Paving the way for innovative solid tumor therapies. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1548234"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1126\/science.aae0491","article-title":"The epigenetic landscape of T cell exhaustion","volume":"354","author":"Sen","year":"2016","journal-title":"Science"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.immuni.2007.09.006","article-title":"Molecular Signature of CD8+ T Cell Exhaustion during Chronic Viral Infection","volume":"27","author":"Wherry","year":"2007","journal-title":"Immunity"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"eabo4997","DOI":"10.1126\/scitranslmed.abo4997","article-title":"Advancing beyond the twists and turns of T cell exhaustion in cancer","volume":"14","author":"Humblin","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1016\/j.immuni.2012.08.021","article-title":"Network Analysis Reveals Centrally Connected Genes and Pathways Involved in CD8+ T Cell Exhaustion versus Memory","volume":"37","author":"Crawford","year":"2012","journal-title":"Immunity"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.coi.2010.01.018","article-title":"Metabolism in T cell activation and differentiation","volume":"22","author":"Pearce","year":"2010","journal-title":"Curr. Opin. Immunol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/s41577-019-0203-y","article-title":"Metabolic coordination of T cell quiescence and activation","volume":"20","author":"Chapman","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1038\/ni.2018","article-title":"Normal T cell homeostasis: The conversion of naive cells into memory-phenotype cells","volume":"12","author":"Sprent","year":"2011","journal-title":"Nat. Immunol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.it.2012.01.007","article-title":"CD8 T cell quiescence revisited","volume":"33","author":"Hamilton","year":"2012","journal-title":"Trends Immunol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1182\/blood-2009-05-220087","article-title":"The CD8+ memory T-cell state of readiness is actively maintained and reversible","volume":"114","author":"Allam","year":"2009","journal-title":"Blood"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.ebiom.2018.11.066","article-title":"FOXP1 negatively regulates tumor infiltrating lymphocyte migration in human breast cancer","volume":"39","author":"Garaud","year":"2019","journal-title":"EBioMedicine"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.immuni.2018.03.025","article-title":"T Cell Receptor-Regulated TGF-beta Type I Receptor Expression Determines T Cell Quiescence and Activation","volume":"48","author":"Tu","year":"2018","journal-title":"Immunity"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Donnenberg, V.S., Luketich, J.D., Popov, B., Bartlett, D.L., and Donnenberg, A.D. (2024). A common secretomic signature across epithelial cancers metastatic to the pleura supports IL-6 axis therapeutic targeting. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1404373"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1245\/s10434-023-14553-6","article-title":"Characterizing the Immune Environment in Peritoneal Carcinomatosis: Insights for Novel Immunotherapy Strategies","volume":"31","author":"Wagner","year":"2024","journal-title":"Ann. Surg. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/cei.12845","article-title":"Interleukin-2 reverses CD8+ T cell exhaustion in clinical malignant pleural effusion of lung cancer","volume":"186","author":"Hu","year":"2016","journal-title":"Clin. Exp. Immunol."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Chen, J., Wei, Y., Yang, W., Huang, Q., Chen, Y., Zeng, K., and Chen, J. (2022). IL-6: The Link Between Inflammation, Immunity and Breast Cancer. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.903800"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s40425-019-0590-4","article-title":"Treatment of malignant pleural effusions: The case for localized immunotherapy","volume":"7","author":"Donnenberg","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.ejca.2008.02.047","article-title":"Systematic review of the association between circulating interleukin-6 (IL-6) and cancer","volume":"44","author":"Ebrahim","year":"2008","journal-title":"Eur. J. Cancer"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"e218","DOI":"10.1016\/S1470-2045(12)70582-X","article-title":"Cytokine patterns in patients with cancer: A systematic review","volume":"14","author":"Lippitz","year":"2013","journal-title":"Lancet Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"eabq2395","DOI":"10.1126\/scitranslmed.abq2395","article-title":"Inhibition of a signaling modality within the gp130 receptor enhances tissue regeneration and mitigates osteoarthritis","volume":"15","author":"Shkhyan","year":"2023","journal-title":"Sci. Transl. Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"E433","DOI":"10.1152\/ajpendo.00074.2003","article-title":"IL-6 enhances plasma IL-1ra, IL-10, and cortisol in humans","volume":"285","author":"Steensberg","year":"2003","journal-title":"Am. J. Physiol.-Endocrinol. Metabolism."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1715064","DOI":"10.1155\/2020\/1715064","article-title":"Prognostic and Clinical Value of Interleukin 6 and CD45+CD14+ Inflammatory Cells with PD-L1+\/PD-L2+ Expression in Patients with Different Manifestation of Ovarian Cancer","volume":"2020","author":"Wertel","year":"2020","journal-title":"J. Immunol. Res."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1007\/s12026-011-8262-6","article-title":"Interleukin 10 in the tumor microenvironment: A target for anticancer immunotherapy","volume":"51","author":"Sato","year":"2011","journal-title":"Immunol. Res."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.canlet.2015.07.009","article-title":"The paradoxical role of IL-10 in immunity and cancer","volume":"367","author":"Mannino","year":"2015","journal-title":"Cancer Lett."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1097\/CCO.0000000000000006","article-title":"Current status of IL-10 and regulatory T-cells in cancer","volume":"25","author":"Dennis","year":"2013","journal-title":"Curr. Opin. Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1615\/CritRevImmunol.v32.i1.30","article-title":"Role of Interleukin 10 Transcriptional Regulation in Inflammation and Autoimmune Disease","volume":"32","author":"Iyer","year":"2012","journal-title":"Crit. Rev.\u2122 Immunol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/s41577-022-00796-z","article-title":"TGF\u03b2 control of immune responses in cancer: A holistic immuno-oncology perspective","volume":"23","author":"Nixon","year":"2023","journal-title":"Nat. Rev. Immunol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.immuni.2019.03.024","article-title":"Transforming Grown Factor-\u03b2 Signaling in Immunity and Cancer","volume":"50","author":"Batlle","year":"2019","journal-title":"Immunity"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/cr.2009.5","article-title":"TGF-\u03b2-induced epithelial to mesenchymal transition","volume":"19","author":"Xu","year":"2009","journal-title":"Cell Res."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.lungcan.2019.11.013","article-title":"Detection of TGF-\u03b2 in pleural effusions for diagnosis and prognostic stratification of malignant pleural mesothelioma","volume":"139","author":"Stockhammer","year":"2020","journal-title":"Lung Cancer"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"3185","DOI":"10.1038\/s41467-018-05489-7","article-title":"T cell-intrinsic IL-1R signaling licenses effector cytokine production by memory CD4 T cells","volume":"9","author":"Jain","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/s41571-019-0175-7","article-title":"Regulatory T cells in cancer immunosuppression\u2014Implications for anticancer therapy","volume":"16","author":"Togashi","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.imbio.2016.10.017","article-title":"Regulatory T cells in malignant pleural effusions subsequent to lung carcinoma and their impact on the course of the disease","volume":"222","author":"Budna","year":"2017","journal-title":"Immunobiology"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s00262-014-1636-6","article-title":"Activated regulatory and memory T-cells accumulate in malignant ascites from ovarian carcinoma patients","volume":"64","author":"Landskron","year":"2014","journal-title":"Cancer Immunol. Immunother. CII"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1002\/cyto.a.23704","article-title":"OMIP-053: Identification, Classification, and Isolation of Major FoxP3 Expressing Human CD4(+) Treg Subsets","volume":"95","author":"Nowatzky","year":"2019","journal-title":"Cytom. A"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"110728","DOI":"10.1016\/j.celrep.2022.110728","article-title":"Human IL-10-producing B cells have diverse states that are induced from multiple B cell subsets","volume":"39","author":"Glass","year":"2022","journal-title":"Cell Rep."},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Takahashi, K., Kurashina, K., Yamaguchi, H., Kanamaru, R., Ohzawa, H., Miyato, H., Saito, S., Hosoya, Y., Lefor, A.K., and Sata, N. (2022). Altered intraperitoneal immune microenvironment in patients with peritoneal metastases from gastric cancer. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.969468"},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Popowicz, N., Cheah, H.M., Gregory, C., Miranda, A., Dick, I.M., Lee, Y.C.G., and Creaney, J. (2021). Neutrophil-to-lymphocyte ratio in malignant pleural fluid: Prognostic significance. PLoS ONE, 16.","DOI":"10.1371\/journal.pone.0250628"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s12935-024-03211-w","article-title":"Immune modulation in malignant pleural effusion: From microenvironment to therapeutic implications","volume":"24","author":"Ge","year":"2024","journal-title":"Cancer Cell Int."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/nri3175","article-title":"Coordinated regulation of myeloid cells by tumours","volume":"12","author":"Gabrilovich","year":"2012","journal-title":"Nat. Rev. Immunol."},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Tobin, R.P., Jordan, K.R., Kapoor, P., Spongberg, E., Davis, D., Vorwald, V.M., Couts, K.L., Gao, D., Smith, D.E., and Borgers, J.S.W. (2019). IL-6 and IL-8 Are Linked With Myeloid-Derived Suppressor Cell Accumulation and Correlate With Poor Clinical Outcomes in Melanoma Patients. Front. Oncol., 9.","DOI":"10.3389\/fonc.2019.01223"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"106","DOI":"10.3892\/or.2021.8057","article-title":"CD244+ polymorphonuclear myeloid-derived suppressor cells reflect the status of peritoneal dissemination in a colon cancer mouse model","volume":"45","author":"Sugita","year":"2021","journal-title":"Oncol. Rep."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1097\/PPO.0000000000000127","article-title":"The Role of Stroma in Tumor Development","volume":"21","author":"Werb","year":"2015","journal-title":"Cancer J."},{"key":"ref_79","unstructured":"Connolly, J.L., Schnitt, S.J., Wang, H.H., Longtine, J.A., Dvorak, A., and Dvorak, H.F. (2003). Tumor Structure and Tumor Stroma Generation. Holland-Frei Cancer Medicine, BC Decker. [6th ed.]."},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Karpathiou, G., P\u00e9oc\u2019h, M., Sundaralingam, A., Rahman, N., and Froudarakis, M.E. (2022). Inflammation of the Pleural Cavity: A Review on Pathogenesis, Diagnosis and Implications in Tumor Pathophysiology. Cancers, 14.","DOI":"10.3390\/cancers14061415"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.resp.2010.12.012","article-title":"Tight junction proteins contribute to barrier properties in human pleura","volume":"175","author":"Markov","year":"2011","journal-title":"Respir. Physiol. Neurobiol."},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Rakina, M., Kazakova, A., Villert, A., Kolomiets, L., and Larionova, I. (2022). Spheroid Formation and Peritoneal Metastasis in Ovarian Cancer: The Role of Stromal and Immune Components. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23116215"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.3390\/cancers7040872","article-title":"The Mesothelial Origin of Carcinoma Associated-Fibroblasts in Peritoneal Metastasis","volume":"7","author":"Sandoval","year":"2015","journal-title":"Cancers"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1038\/ncb3041","article-title":"A breast cancer stem cell niche supported by juxtacrine signalling from monocytes and macrophages","volume":"16","author":"Lu","year":"2014","journal-title":"Nat. Cell Biol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"26750","DOI":"10.1074\/jbc.M116.753236","article-title":"Malignant Pleural Effusion and ascites Induce Epithelial-Mesenchymal Transition and Cancer Stem-like Cell Properties via the Vascular Endothelial Growth Factor (VEGF)\/Phosphatidylinositol 3-Kinase (PI3K)\/Akt\/Mechanistic Target of Rapamycin (mTOR) Pathway","volume":"291","author":"Yin","year":"2016","journal-title":"J. Biol. Chem."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"3575","DOI":"10.1007\/s13277-013-1472-x","article-title":"Transforming growth factor-beta1 signaling blockade attenuates gastric cancer cell-induced peritoneal mesothelial cell fibrosis and alleviates peritoneal dissemination both in vitro and in vivo","volume":"35","author":"Miao","year":"2014","journal-title":"Tumour Biol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"215597","DOI":"10.1016\/j.canlet.2022.215597","article-title":"Macrophages are primed to transdifferentiate into fibroblasts in malignant ascites and pleural effusions","volume":"532","author":"Ito","year":"2022","journal-title":"Cancer Lett."},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Lorenc, E., Varinelli, L., Chighizola, M., Brich, S., Pisati, F., Guaglio, M., Baratti, D., Deraco, M., Gariboldi, M., and Podest\u00e0, A. (2023). Correlation between biological and mechanical properties of extracellular matrix from colorectal peritoneal metastases in human tissues. Sci. Rep., 13.","DOI":"10.1038\/s41598-023-38763-w"},{"key":"ref_89","first-page":"4447","article-title":"Intraperitoneal recombinant alpha-interferon for \u201csalvage\u201d immunotherapy in stage III epithelial ovarian cancer: A Gynecologic Oncology Group Study","volume":"45","author":"Berek","year":"1985","journal-title":"Cancer Res."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1007\/BF02469915","article-title":"Effects of intraperitoneal administration of OK-432 for patients with advanced cancer","volume":"15","author":"Toge","year":"1985","journal-title":"Jpn. J. Surg."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.medj.2024.02.003","article-title":"Phase 1b study of intraperitoneal ipilimumab and nivolumab in patients with recurrent gynecologic malignancies with peritoneal carcinomatosis","volume":"5","author":"Knisely","year":"2024","journal-title":"Med"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"4015","DOI":"10.1200\/JCO.2015.62.3397","article-title":"Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer","volume":"33","author":"Hamanishi","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/S0140-6736(17)31827-5","article-title":"Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"Kang","year":"2017","journal-title":"Lancet"},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Zhang, L., Mai, W., Jiang, W., and Geng, Q. (2020). Sintilimab: A Promising Anti-Tumor PD-1 Antibody. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.594558"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"S349","DOI":"10.1016\/j.jtho.2021.01.551","article-title":"P16.05 Exploratory Study of Sintilimab Intrapleural Therapy for NSCLC-Mediated Malignant Pleural Effusion","volume":"16","author":"Lv","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"ref_96","first-page":"1103","article-title":"Multicenter phase 2 study of intrapleural nivolumab in patients with metastatic non-small cell lung cancer and pleural effusion","volume":"13","author":"Tsimafeyeu","year":"2023","journal-title":"Am. J. Cancer Res."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.4103\/jcrt.jcrt_739_22","article-title":"Intrapleural nivolumab in cancer patients with pleural effusion","volume":"20","author":"Tsimafeyeu","year":"2024","journal-title":"J. Cancer Res. Ther."},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Hossen, M.M., Ma, Y., Yin, Z., Xia, Y., Du, J., Huang, J.Y., Huang, J.J., Zou, L., Ye, Z., and Huang, Z. (2023). Current understanding of CTLA-4: From mechanism to autoimmune diseases. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1198365"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1159\/000490025","article-title":"Evolving Roles for Targeting CTLA-4 in Cancer Immunotherapy","volume":"47","author":"Zhao","year":"2018","journal-title":"Cell. Physiol. Biochem."},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Kooshkaki, O., Derakhshani, A., Hosseinkhani, N., Torabi, M., Safaei, S., Brunetti, O., Racanelli, V., Silvestris, N., and Baradaran, B. (2020). Combination of Ipilimumab and Nivolumab in Cancers: From Clinical Practice to Ongoing Clinical Trials. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21124427"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"e1554969","DOI":"10.1080\/2162402X.2018.1554969","article-title":"Making cold malignant pleural effusions hot: Driving novel immunotherapies","volume":"8","author":"Murthy","year":"2019","journal-title":"Oncoimmunology"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1093\/jnci\/djt093","article-title":"Effect of Tumor Microenvironment on Tumor VEGF During Anti-VEGF Treatment: Systems Biology Predictions","volume":"105","author":"Finley","year":"2013","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s10434-999-0373-0","article-title":"Markedly Elevated Levels of Vascular Endothelial Growth Factor in Malignant Ascites","volume":"6","author":"Zebrowski","year":"1999","journal-title":"Ann. Surg. Oncol."},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"Zeng, H., Zhang, Y., Tan, S., Huang, Q., Pu, X., Tian, P., and Li, Y. (2024). Efficacy of bevacizumab through an indwelling pleural catheter in non-small cell lung cancer patients with symptomatic malignant pleural effusion. BMC Pulm. Med., 24.","DOI":"10.1186\/s12890-024-02886-1"},{"key":"ref_105","first-page":"e41","article-title":"Bevacizumab in Addition to Palliative Chemotherapy for Patients With Peritoneal Carcinomatosis of Colorectal Origin: A Nationwide Population-Based Study","volume":"15","author":"Razenberg","year":"2016","journal-title":"Clin. Color. Cancer"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.ygyno.2021.02.002","article-title":"REZOLVE (ANZGOG-1101): A phase 2 trial of intraperitoneal bevacizumab to treat symptomatic ascites in patients with chemotherapy-resistant, epithelial ovarian cancer","volume":"161","author":"Sjoquist","year":"2021","journal-title":"Gynecol. Oncol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ejca.2016.05.004","article-title":"Intraperitoneal bevacizumab for control of malignant ascites due to advanced-stage gastrointestinal cancers: A multicentre double-blind, placebo-controlled phase II study\u2014AIO SUP-0108","volume":"63","author":"Jordan","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.1111\/jcpt.13781","article-title":"Evaluation of the Tocilizumab therapy in human cancers: Latest evidence and clinical potential","volume":"47","author":"Ghasemi","year":"2022","journal-title":"J. Clin. Pharm. Ther."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"100045","DOI":"10.1016\/j.soi.2024.100045","article-title":"Intra-pleural and intra-peritoneal tocilizumab therapy for managing malignant pleural effusions and ascites: The Regional Immuno-Oncology Trial (RIOT)\u20142 Study protocol","volume":"1","author":"Park","year":"2024","journal-title":"Surg. Oncol. Insight"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"3583","DOI":"10.1016\/j.apsb.2023.05.023","article-title":"Bispecific antibodies in cancer therapy: Target selection and regulatory requirements","volume":"13","author":"Sun","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/s41416-018-0150-6","article-title":"Randomised phase II trial to investigate catumaxomab (anti-EpCAM \u00d7 anti-CD3) for treatment of peritoneal carcinomatosis in patients with gastric cancer","volume":"119","author":"Kunzmann","year":"2018","journal-title":"Br. J. Cancer"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"3899","DOI":"10.1158\/1078-0432.CCR-06-2769","article-title":"Effective Relief of Malignant Ascites in Patients with Advanced Ovarian Cancer by a Trifunctional Anti-EpCAM \u00d7 Anti-CD3 Antibody: A Phase I\/II Study","volume":"13","author":"Burges","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1002\/ijc.25423","article-title":"The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II\/III trial","volume":"127","author":"Heiss","year":"2010","journal-title":"Int. J. Cancer"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"3046","DOI":"10.1200\/jco.2007.25.18_suppl.3046","article-title":"Effects of the trifunctional antibody catumaxomab (anti-EpCAM \u00d7 anti-CD3) on proliferation and cytokine secretion of immune cells in malignant pleural effusion","volume":"25","author":"Sebastian","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"S1427","DOI":"10.1016\/j.annonc.2024.10.082","article-title":"Updated results of a phase II trial evaluating an anti-EpCAM \u00d7 anti-CD3 bispecific antibody, M701, for the treatment of malignant ascites","volume":"35","author":"Liu","year":"2024","journal-title":"Ann. Oncol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"S862","DOI":"10.1016\/j.annonc.2024.08.1426","article-title":"1371P An anti-EpCAM \u00d7 CD3 bispecific antibody, M701, for the treatment of malignant pleural effusion in NSCLC patients: Intermediate results of a prospective multicenter phase Ib trial","volume":"35","author":"Cai","year":"2024","journal-title":"Ann. Oncol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"229","DOI":"10.5501\/wjv.v10.i5.229","article-title":"Oncolytic virus therapy in cancer: A current review","volume":"10","year":"2021","journal-title":"World J. Virol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/cgt.2014.31","article-title":"Oncolytic viruses as platform for multimodal cancer therapeutics: A promising land","volume":"21","author":"Guo","year":"2014","journal-title":"Cancer Gene Ther."},{"key":"ref_119","first-page":"1","article-title":"Oncolytic virotherapy: Basic principles, recent advances and future directions","volume":"8","author":"Lin","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_120","first-page":"8751","article-title":"Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes","volume":"61","author":"McCart","year":"2001","journal-title":"Cancer Res."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"e000710","DOI":"10.1136\/jitc-2020-000710","article-title":"Oncolytic vaccinia virus delivering tethered IL-12 enhances antitumor effects with improved safety","volume":"8","author":"Ge","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1038\/mt.2016.101","article-title":"Phase 1 Study of Intravenous Oncolytic Poxvirus (vvDD) in Patients With Advanced Solid Cancers","volume":"24","author":"Guo","year":"2016","journal-title":"Mol. Ther."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"25","DOI":"10.5662\/wjm.v6.i1.25","article-title":"Clinical development of reovirus for cancer therapy: An oncolytic virus with immune-mediated antitumor activity","volume":"6","author":"Gong","year":"2016","journal-title":"World J. Methodol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"e007552","DOI":"10.1136\/jitc-2023-007552","article-title":"ONCOS-102 plus pemetrexed and platinum chemotherapy in malignant pleural mesothelioma: A randomized phase 2 study investigating clinical outcomes and the tumor microenvironment","volume":"11","author":"Ponce","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"ref_125","doi-asserted-by":"crossref","unstructured":"Wong, M.K., Milhem, M.M., Sacco, J.J., Michels, J., In, G.K., Munoz Couselo, E., Schadendorf, D., Beasley, G.M., Niu, J., and Chmielowski, B. (2025). RP1 Combined With Nivolumab in Advanced Anti-PD-1-Failed Melanoma (IGNYTE). J. Clin. Oncol., JCO2501346.","DOI":"10.1200\/JCO-25-01346"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"4388","DOI":"10.1158\/1078-0432.CCR-18-0244","article-title":"Phase I Study of Oncolytic Vaccinia Virus GL-ONC1 in Patients with Peritoneal Carcinomatosis","volume":"24","author":"Lauer","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/1479-5876-11-106","article-title":"Treatment of malignant effusion by oncolytic virotherapy in an experimental subcutaneous xenograft model of lung cancer","volume":"11","author":"Weibel","year":"2013","journal-title":"J. Transl. Med."},{"key":"ref_128","doi-asserted-by":"crossref","unstructured":"Giehl, E., Kosaka, H., Liu, Z., Feist, M., Kammula, U.S., Lotze, M.T., Ma, C., Guo, Z.S., and Bartlett, D.L. (2021). In Vivo Priming of Peritoneal Tumor-Reactive Lymphocytes with a Potent Oncolytic Virus for Adoptive Cell Therapy. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.610042"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"e000857","DOI":"10.1136\/jitc-2020-000857","article-title":"Oncolytic vaccinia virus reinvigorates peritoneal immunity and cooperates with immune checkpoint inhibitor to suppress peritoneal carcinomatosis in colon cancer","volume":"8","author":"Lee","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"ref_130","doi-asserted-by":"crossref","unstructured":"Chee, J., Watson, M.W., Chopra, A., Nguyen, B., Cook, A.M., Creaney, J., Lesterhuis, W.J., Robinson, B.W., Lee, Y.C.G., and Nowak, A.K. (2018). Tumour associated lymphocytes in the pleural effusions of patients with mesothelioma express high levels of inhibitory receptors. BMC Res. Notes, 11.","DOI":"10.1186\/s13104-018-3953-x"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"e122467","DOI":"10.1172\/jci.insight.122467","article-title":"Enhanced detection of neoantigen-reactive T cells targeting unique and shared oncogenes for personalized cancer immunotherapy","volume":"3","author":"Yossef","year":"2018","journal-title":"JCI Insight"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1158\/0008-5472.CAN-17-2153","article-title":"Enhanced Lymphodepletion Is Insufficient to Replace Exogenous IL2 or IL15 Therapy in Augmenting the Efficacy of Adoptively Transferred Effector CD8+ T Cells","volume":"78","author":"Johnson","year":"2018","journal-title":"Cancer Res."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1097\/00002371-199410000-00004","article-title":"Intraperitoneal Adoptive Immunotherapy of Ovarian Carcinoma with Tumor-Infiltrating Lymphocytes and Low-Dose Recombinant Interleukin-2: A Pilot Trial","volume":"16","author":"Freedman","year":"1994","journal-title":"J. Immunother."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"e008735","DOI":"10.1136\/jitc-2023-008735","article-title":"Expert consensus guidelines on management and best practices for tumor-infiltrating lymphocyte cell therapy","volume":"12","author":"Hamid","year":"2024","journal-title":"J. Immunother. Cancer."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1200\/JCO.21.02170","article-title":"Breast Cancers Are Immunogenic: Immunologic Analyses and a Phase II Pilot Clinical Trial Using Mutation-Reactive Autologous Lymphocytes","volume":"40","author":"Zacharakis","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1038\/s41423-020-00565-9","article-title":"Tumor-infiltrating lymphocytes in the immunotherapy era","volume":"18","author":"Paijens","year":"2021","journal-title":"Cell. Mol. Immunol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"867","DOI":"10.2340\/1651-226X.2024.40495","article-title":"NIVO-TIL: Combination anti-PD-1 therapy and adoptive T-cell transfer in untreated metastatic melanoma: An exploratory open-label phase I trial","volume":"63","author":"Lancien","year":"2024","journal-title":"Acta Oncol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s13287-020-02128-1","article-title":"CAR T cells in solid tumors: Challenges and opportunities","volume":"12","author":"Marofi","year":"2021","journal-title":"Stem Cell Res. Ther."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1182\/blood-2016-02-629063","article-title":"CD19-targeted CAR T-cell therapeutics for hematologic malignancies: Interpreting clinical outcomes to date","volume":"127","author":"Park","year":"2016","journal-title":"Blood"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.1158\/2159-8290.CD-21-0407","article-title":"A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti\u2013PD-1 Agent Pembrolizumab","volume":"11","author":"Adusumilli","year":"2021","journal-title":"Cancer Discov."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1038\/s41591-024-02893-z","article-title":"Intrathecal bivalent CAR T cells targeting EGFR and IL13Ralpha2 in recurrent glioblastoma: Phase 1 trial interim results","volume":"30","author":"Bagley","year":"2024","journal-title":"Nat. Med."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1158\/2159-8290.CD-15-0583","article-title":"Mesothelin-Targeted CARs: Driving T Cells to Solid Tumors","volume":"6","author":"Morello","year":"2016","journal-title":"Cancer Discov."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"100728","DOI":"10.1016\/j.crmeth.2024.100728","article-title":"An engineering strategy to target activated EGFR with CAR T cells","volume":"4","author":"Dobersberger","year":"2024","journal-title":"Cell Rep. Methods"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/cgt.2016.14","article-title":"Regional CAR-T cell infusions for peritoneal carcinomatosis are superior to systemic delivery","volume":"23","author":"Katz","year":"2016","journal-title":"Cancer Gene Ther."},{"key":"ref_145","doi-asserted-by":"crossref","unstructured":"Murad, J.P., Kozlowska, A.K., Lee, H.J., Ramamurthy, M., Chang, W.-C., Yazaki, P., Colcher, D., Shively, J., Cristea, M., and Forman, S.J. (2018). Effective Targeting of TAG72+ Peritoneal Ovarian Tumors via Regional Delivery of CAR-Engineered T Cells. Front. Immunol., 9.","DOI":"10.3389\/fimmu.2018.02268"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s41030-025-00301-6","article-title":"A Diagnostic Approach to Malignant Pleural Mesothelioma","volume":"11","author":"Aujayeb","year":"2025","journal-title":"Pulm. Ther."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.lungcan.2021.05.004","article-title":"CAR T-cell therapy for pleural mesothelioma: Rationale, preclinical development, and clinical trials","volume":"157","author":"Chintala","year":"2021","journal-title":"Lung Cancer"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"e123","DOI":"10.1016\/j.bbmt.2018.12.756","article-title":"Cytokine Release Syndrome with Chimeric Antigen Receptor T Cell Therapy","volume":"25","author":"Frey","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jim.2016.03.005","article-title":"Measuring IL-6 and sIL-6R in serum from patients treated with tocilizumab and\/or siltuximab following CAR T cell therapy","volume":"434","author":"Chen","year":"2016","journal-title":"J. Immunol. Methods"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"e1211218","DOI":"10.1080\/2162402X.2016.1211218","article-title":"Efficient tumor regression by adoptively transferred CEA-specific CAR-T cells associated with symptoms of mild cytokine release syndrome","volume":"5","author":"Wang","year":"2016","journal-title":"Oncoimmunology"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"e186268","DOI":"10.1172\/jci.insight.186268","article-title":"Affinity-tuned mesothelin CAR T cells demonstrate enhanced targeting specificity and reduced off-tumor toxicity","volume":"9","author":"Yang","year":"2024","journal-title":"JCI Insight"},{"key":"ref_152","doi-asserted-by":"crossref","unstructured":"Donnenberg, V.S., Lister, J., Briedenbaugh, C.L., Wagner, P., Bartlett, D., and Donnenberg, A.D. (2025). Fast TIL: Rapid Manufacture of an Adoptive Cellular Therapeutic from Pleural Infiltrating T cells for Intrapleural Administration. Cytotherapy, in press.","DOI":"10.1016\/j.jcyt.2025.06.011"},{"key":"ref_153","first-page":"4587","article-title":"Better Clinical Efficiency of TILs for Malignant Pleural Effusion and Ascites than Cisplatin Through Intrapleural and Intraperitoneal Infusion","volume":"37","author":"Chu","year":"2017","journal-title":"Anticancer. Res."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/19\/3217\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T04:27:25Z","timestamp":1759552045000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/19\/3217"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,2]]},"references-count":153,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["cancers17193217"],"URL":"https:\/\/doi.org\/10.3390\/cancers17193217","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,2]]}}}